FR21C1064I1 - Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire - Google Patents
Compositions et procedes de traitement de troubles impliquant une proliferation cellulaireInfo
- Publication number
- FR21C1064I1 FR21C1064I1 FR21C1064C FR21C1064I1 FR 21C1064 I1 FR21C1064 I1 FR 21C1064I1 FR 21C1064 C FR21C1064 C FR 21C1064C FR 21C1064 I1 FR21C1064 I1 FR 21C1064I1
- Authority
- FR
- France
- Prior art keywords
- methods
- compositions
- cellular proliferation
- treating disorders
- disorders involving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004663 cell proliferation Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63983404P | 2004-12-28 | 2004-12-28 | |
US70455105P | 2005-08-01 | 2005-08-01 | |
US72734105P | 2005-10-17 | 2005-10-17 | |
PCT/US2005/047333 WO2006071960A2 (fr) | 2004-12-28 | 2005-12-28 | Compositions et procedes de traitement de troubles de la proliferation cellulaire |
Publications (2)
Publication Number | Publication Date |
---|---|
FR21C1064I1 true FR21C1064I1 (fr) | 2022-02-18 |
FR21C1064I2 FR21C1064I2 (fr) | 2022-11-18 |
Family
ID=36615518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR21C1064C Active FR21C1064I2 (fr) | 2004-12-28 | 2021-12-22 | Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire |
Country Status (17)
Country | Link |
---|---|
US (5) | US7300931B2 (fr) |
EP (1) | EP1836169B9 (fr) |
JP (2) | JP5124285B2 (fr) |
KR (2) | KR101478933B1 (fr) |
CN (2) | CN101184734B (fr) |
AT (1) | ATE544748T1 (fr) |
AU (1) | AU2005321966B2 (fr) |
BR (1) | BRPI0519424B8 (fr) |
CA (1) | CA2594345C (fr) |
DK (1) | DK1836169T5 (fr) |
ES (1) | ES2382068T3 (fr) |
FR (1) | FR21C1064I2 (fr) |
HK (2) | HK1108695A1 (fr) |
HU (1) | HUS2100051I1 (fr) |
NL (1) | NL301145I2 (fr) |
PL (1) | PL1836169T3 (fr) |
WO (1) | WO2006071960A2 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7300931B2 (en) | 2004-12-28 | 2007-11-27 | Kinex Pharmaceuticals, Llc | Compositions for treating cell proliferation disorders |
US7968574B2 (en) * | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
JP5186219B2 (ja) | 2005-01-25 | 2013-04-17 | エピックス デラウェア, インコーポレイテッド | 置換アリールアミン化合物および5−ht6調節因子としてのその使用 |
AU2007265373B2 (en) * | 2006-06-29 | 2013-02-21 | Atnx Spv, Llc | Biaryl compositions and methods for modulating a kinase cascade |
DK2041071T3 (da) * | 2006-06-29 | 2014-09-01 | Kinex Pharmaceuticals Llc | Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade |
AU2014200559B2 (en) * | 2006-12-28 | 2016-05-26 | Atnx Spv, Llc | Composition and Methods for Modulating a Kinase Cascade |
US7939529B2 (en) * | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
US20210198202A1 (en) * | 2006-12-28 | 2021-07-01 | Athenex, Inc. | Compositions for modulating a kinase cascade and methods of use thereof |
US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
TWI457336B (zh) * | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
WO2008127727A1 (fr) * | 2007-04-13 | 2008-10-23 | Kinex Pharmaceuticals, Llc | Compositions de biaryle et procédés de modulation d'une cascade de kinases |
AU2014202221B2 (en) * | 2007-05-17 | 2016-06-23 | Atnx Spv, Llc | Process for the Preparation of Compositions for Modulating a Kinase Cascade and Methods of Use Thereof |
AU2008254500B2 (en) * | 2007-05-17 | 2014-01-23 | Atnx Spv, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
US8124605B2 (en) | 2007-07-06 | 2012-02-28 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
CN105796568A (zh) | 2007-10-20 | 2016-07-27 | 阿西纳斯公司 | 用于调控激酶级联的药物组合物及其使用方法 |
US8598165B2 (en) | 2007-11-26 | 2013-12-03 | University Of Kansas | Morpholines as selective inhibitors of cytochrome P450 2A13 |
CN101977905B (zh) | 2008-01-23 | 2014-07-02 | 百时美施贵宝公司 | 4-吡啶酮化合物及其对于癌症的用途 |
TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基-雜芳基衍生物及其使用方法 |
WO2011129936A2 (fr) | 2010-04-16 | 2011-10-20 | Kinex Pharmaceuticals, Llc | Compositions et procédés pour la prévention et le traitement du cancer |
EP2590946B1 (fr) | 2010-07-05 | 2015-02-18 | Merck Patent GmbH | Dérivés de bipyridyl utiles pour le traitement de maladies induites par des kinases |
PE20141581A1 (es) | 2011-09-27 | 2014-11-14 | Novartis Ag | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante |
KR101415742B1 (ko) * | 2011-12-21 | 2014-07-04 | 영남대학교 산학협력단 | 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
CN102746255A (zh) * | 2012-07-24 | 2012-10-24 | 安徽中医学院 | 具有抗肿瘤活性的化合物、制备方法及应用 |
US9926273B2 (en) * | 2012-08-30 | 2018-03-27 | Athenex, Inc. | Composition and methods for modulating a kinase cascade |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
ME03780B (fr) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Dérivés de thiazolecarboxamide et pyridinecarboxamide et leur utilisation comme inhibiteurs des kinases pim |
ES2665619T3 (es) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante |
WO2015027124A1 (fr) | 2013-08-23 | 2015-02-26 | Incyte Corporation | Composés de furo- et thiéno-pyridinecarboxamide utiles en tant qu'inhibiteurs de kinases pim |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
MY181913A (en) * | 2014-09-10 | 2021-01-14 | Glaxosmithkline Ip Dev Ltd | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
CN106902358B (zh) * | 2015-12-21 | 2020-07-10 | 广州市香雪制药股份有限公司 | 口服制剂及其制备方法 |
CN106902357B (zh) * | 2015-12-21 | 2021-08-03 | 广州市香雪制药股份有限公司 | 药物组合物及其应用、药物包合物、静脉制剂及制备方法 |
US10213435B2 (en) | 2016-08-12 | 2019-02-26 | Athenex, Inc. | Biaryl compositions and methods for modulating a kinase cascade |
CN106810490A (zh) * | 2017-02-06 | 2017-06-09 | 重庆泰润制药有限公司 | 一种二芳基化合物的晶型及其制备方法和应用 |
JP2020510042A (ja) | 2017-03-10 | 2020-04-02 | アセネックス インコーポレイテッド | 光線角化症を治療および/または予防する方法 |
KR20240038149A (ko) | 2017-04-26 | 2024-03-22 | 바실리어 파마슈티카 인터내셔널 리미티드 | 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정 |
CA3074831A1 (fr) | 2017-09-07 | 2019-03-14 | Athenex HK Innovative Limited | Formes solides de 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CN113117376B (zh) * | 2019-12-30 | 2022-08-19 | 中国科学院高能物理研究所 | 一种邻菲罗啉衍生的萃取剂及其制法和应用 |
CN113461665B (zh) * | 2020-03-31 | 2023-05-19 | 成都赜灵生物医药科技有限公司 | 二芳基衍生物及其制备方法和用途 |
CN113354575B (zh) * | 2021-06-07 | 2022-09-27 | 河南应用技术职业学院 | 一种特班布林的合成方法 |
EP4186890A1 (fr) | 2021-11-29 | 2023-05-31 | Moehs Ibérica, S.L. | Préparation de n-benzyl-2-(5-bromo-pyridin-2-yl)-acétamide pour la synthèse de la tirbanibuline |
WO2023134751A1 (fr) * | 2022-01-14 | 2023-07-20 | 武汉人福创新药物研发中心有限公司 | Inhibiteur double cible de tubuline-src et son utilisation |
WO2023134753A1 (fr) * | 2022-01-14 | 2023-07-20 | 武汉人福创新药物研发中心有限公司 | Inhibiteur double cible de tubuline-src |
EP4302831A1 (fr) | 2022-07-04 | 2024-01-10 | Trifarma S.p.A. | Procédé de synthèse de tirbanibulin |
CN115073362A (zh) * | 2022-08-04 | 2022-09-20 | 重庆迈德凯医药有限公司 | 一种替尼布林的合成方法 |
CN117624139A (zh) * | 2022-08-25 | 2024-03-01 | 武汉人福创新药物研发中心有限公司 | 二芳基类化合物及其制备方法和用途 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3761477A (en) * | 1968-11-08 | 1973-09-25 | Mc Neil Labor Inc | Pyrazineacetic acids, lower alkyl esters, amides and salts |
IT1044222B (it) * | 1972-05-23 | 1980-03-20 | Zambeletti Spa L | Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata |
AT341512B (de) | 1975-01-09 | 1978-02-10 | Thomae Gmbh Dr K | Verfahren zur herstellung von neuen biphenylathern |
CA1261835A (fr) * | 1984-08-20 | 1989-09-26 | Masaaki Toda | Benz(thio) amides fusionnes |
JPS62252755A (ja) * | 1986-04-11 | 1987-11-04 | Daikin Ind Ltd | 新規n−ベンジルベンズアミド誘導体およびこれを有効成分として含有する除草剤 |
US5232948A (en) | 1990-09-10 | 1993-08-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted monocyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity |
CH685875A5 (fr) | 1991-04-26 | 1995-10-31 | Pierre Baudet | Les N-phényl-benzamides protecteurs contre les effets nocifs de la lumière ultra-violette |
AU658188B2 (en) | 1991-05-20 | 1995-04-06 | Tsumura & Co. | Phellodendrine analogs and allergy type IV suppressor containing the same as active ingredient |
DE4236103A1 (de) | 1992-10-26 | 1994-04-28 | Hoechst Ag | Verfahren zur Kreuzkupplung von aromatischen Boronsäuren mit aromatischen Halogenverbindungen oder Perfluoralkylsulfonaten |
US5643957A (en) * | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
FR2705671B1 (fr) * | 1993-05-26 | 1995-07-07 | Inst Nat Sante Rech Med | Nouveaux dérivés de l'hydroxybiphényle, leur préparation et les compositions pharmaceutiques qui les contiennent. |
CA2144669A1 (fr) * | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Derives du biphenyle |
FR2737721B1 (fr) * | 1995-08-08 | 1997-09-05 | Roussel Uclaf | Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant |
AU4885097A (en) * | 1996-11-08 | 1998-06-03 | Sankyo Company Limited | Arylureas or arylmethylcarbamoyl derivatives |
ZA985542B (en) * | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
JP2001023259A (ja) | 1999-07-09 | 2001-01-26 | Sony Corp | 光磁気記録媒体およびその製造方法 |
US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
MX226123B (es) | 1999-09-17 | 2005-02-07 | Millennium Pharm Inc | Benzamidas e inhibidores del factor xa relacionadas. |
US6372752B1 (en) * | 2000-02-07 | 2002-04-16 | Genzyme Corporation | Inha inhibitors and methods of use thereof |
US20040039048A1 (en) * | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
KR100423899B1 (ko) | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
AU2001269821A1 (en) | 2000-06-15 | 2001-12-24 | Barbara Chen | Cycloalkyl alkanoic acids as integrin receptor antagonists |
US6376524B1 (en) * | 2000-06-21 | 2002-04-23 | Sunesis Pharmaceuticals, Inc. | Triphenyl compounds as interleukin-4 antagonists |
JP2002020362A (ja) * | 2000-07-06 | 2002-01-23 | Nippon Oruganon Kk | 新規ビフェニル誘導体 |
US6624180B2 (en) * | 2000-11-20 | 2003-09-23 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
CA2441733A1 (fr) | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de kinases n-terminales c-jun (jnk) et autres proteineskinases |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
DE10201764A1 (de) * | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
JP2003231633A (ja) * | 2002-02-06 | 2003-08-19 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
MXPA04007584A (es) | 2002-02-07 | 2004-12-06 | Wisconsin Alumni Res Found | Compuestos de poliamina y composiciones para su uso en conjunto con una terapia contra el cancer. |
JP2005517007A (ja) * | 2002-02-07 | 2005-06-09 | アクシス・ファーマスーティカルズ | ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート |
FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
DE10219294A1 (de) | 2002-04-25 | 2003-11-13 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
GB0209891D0 (en) | 2002-04-30 | 2002-06-05 | Glaxo Group Ltd | Novel compounds |
CA2484209C (fr) | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Modulateurs de proteine kinase et procedes d'utilisation |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
SE0201937D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
AU2003254177A1 (en) | 2002-07-31 | 2004-02-16 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
AU2003250701A1 (en) | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
WO2004014279A2 (fr) | 2002-08-07 | 2004-02-19 | Mauro Xavier | Veste flottante d'elongation sacro-lombaire |
DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US20040242572A1 (en) * | 2002-08-24 | 2004-12-02 | Boehringer Ingelheim International Gmbh | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture |
ATE454378T1 (de) | 2002-11-01 | 2010-01-15 | Vertex Pharma | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen |
CA2504941C (fr) | 2002-11-08 | 2012-06-26 | Neurogen Corporation | 6-arylpyridines substituees en position 3 |
JP4896518B2 (ja) | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
EP1575918A2 (fr) | 2002-12-19 | 2005-09-21 | Neurogen Corporation | Analogues d'arylamide d'acide biphenyl-4-carboxylique substitues comme modulateurs du recepteur de la capsaicine |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
US6969726B2 (en) * | 2003-06-03 | 2005-11-29 | Rib X Pharmaceuticals Inc | Biaryl heterocyclic compounds and methods of making and using the same |
WO2005014532A1 (fr) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Composes aryle et heteroaryle, compositions et procedes associes |
WO2005013914A2 (fr) | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants |
WO2005032493A2 (fr) * | 2003-10-07 | 2005-04-14 | Renovis, Inc. | Composes d'amides utilises en tant que ligands de canaux ioniques et utilisations correspondantes |
KR20080042188A (ko) * | 2003-11-05 | 2008-05-14 | 에프. 호프만-라 로슈 아게 | Ppar 작용제로서 페닐 유도체 |
PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
JP2008508348A (ja) | 2004-08-02 | 2008-03-21 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ | 銅含有アミンオキシダーゼを阻害するための化合物およびその使用 |
US7300931B2 (en) | 2004-12-28 | 2007-11-27 | Kinex Pharmaceuticals, Llc | Compositions for treating cell proliferation disorders |
US7968574B2 (en) * | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
CN101253152A (zh) | 2005-09-02 | 2008-08-27 | 安斯泰来制药株式会社 | 作为rock抑制剂的酰胺衍生物 |
WO2007095383A2 (fr) | 2006-02-15 | 2007-08-23 | Myriad Genetics, Inc. | Promédicaments |
CA2858520A1 (fr) | 2006-05-18 | 2007-11-29 | Pharmacyclics Inc. | Inhibiteurs de kinases intracellulaires |
AU2007265373B2 (en) | 2006-06-29 | 2013-02-21 | Atnx Spv, Llc | Biaryl compositions and methods for modulating a kinase cascade |
DK2041071T3 (da) | 2006-06-29 | 2014-09-01 | Kinex Pharmaceuticals Llc | Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade |
EP2518063B1 (fr) * | 2006-12-21 | 2017-02-01 | Sloan-Kettering Institute For Cancer Research | Composés contenant des pyridazinones et furan |
US7935697B2 (en) * | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
US7939529B2 (en) * | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
TWI457336B (zh) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
WO2008127727A1 (fr) | 2007-04-13 | 2008-10-23 | Kinex Pharmaceuticals, Llc | Compositions de biaryle et procédés de modulation d'une cascade de kinases |
US8124605B2 (en) | 2007-07-06 | 2012-02-28 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
WO2011129936A2 (fr) * | 2010-04-16 | 2011-10-20 | Kinex Pharmaceuticals, Llc | Compositions et procédés pour la prévention et le traitement du cancer |
-
2005
- 2005-12-28 US US11/321,419 patent/US7300931B2/en active Active
- 2005-12-28 CN CN2005800487967A patent/CN101184734B/zh active Active
- 2005-12-28 EP EP05855828A patent/EP1836169B9/fr active Active
- 2005-12-28 WO PCT/US2005/047333 patent/WO2006071960A2/fr active Application Filing
- 2005-12-28 ES ES05855828T patent/ES2382068T3/es active Active
- 2005-12-28 KR KR1020137015670A patent/KR101478933B1/ko active IP Right Grant
- 2005-12-28 KR KR1020077017102A patent/KR101328273B1/ko active IP Right Grant
- 2005-12-28 AT AT05855828T patent/ATE544748T1/de active
- 2005-12-28 CN CN201310139459.5A patent/CN103274961B/zh active Active
- 2005-12-28 BR BRPI0519424A patent/BRPI0519424B8/pt active IP Right Grant
- 2005-12-28 PL PL05855828T patent/PL1836169T3/pl unknown
- 2005-12-28 JP JP2007549605A patent/JP5124285B2/ja active Active
- 2005-12-28 AU AU2005321966A patent/AU2005321966B2/en active Active
- 2005-12-28 DK DK05855828.9T patent/DK1836169T5/da active
- 2005-12-28 CA CA2594345A patent/CA2594345C/fr active Active
-
2007
- 2007-04-26 US US11/796,200 patent/US8003641B2/en active Active
-
2008
- 2008-03-07 HK HK08102720.5A patent/HK1108695A1/xx unknown
-
2010
- 2010-11-19 US US12/950,764 patent/US8980890B2/en active Active
-
2012
- 2012-01-19 JP JP2012009251A patent/JP2012082222A/ja not_active Withdrawn
-
2014
- 2014-03-03 HK HK14102102.5A patent/HK1188985A1/zh unknown
-
2015
- 2015-03-16 US US14/658,736 patent/US9655903B2/en active Active
-
2021
- 2021-11-16 HU HUS2100051C patent/HUS2100051I1/hu unknown
- 2021-11-18 NL NL301145C patent/NL301145I2/nl unknown
- 2021-12-22 FR FR21C1064C patent/FR21C1064I2/fr active Active
-
2023
- 2023-02-16 US US18/110,416 patent/US20240050438A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR21C1064I2 (fr) | Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire | |
EA201070238A1 (ru) | Соединения пиримидина | |
MX2007008137A (es) | Triazoloftalazinas como inhibidores de pde2. | |
ZA200701137B (en) | Triazolophthalazines | |
MY149957A (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
TW200640924A (en) | VEGF-R2 inhibitors and methods | |
DK1893196T3 (da) | Diarylhydantoin-forbindelse | |
NO20076413L (no) | Multisykliske forbindelser og fremgangsmater for deres anvendelse | |
NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
GEP20084550B (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
DE602007006961D1 (de) | Cgrp-rezeptorantagonisten | |
EA200701467A1 (ru) | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) | |
WO2008011071A3 (fr) | Interactions des voies de signaux hedgehog et du récepteur x hépatique | |
EA201000494A1 (ru) | Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4 | |
NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
TW200724140A (en) | Hydantoin compounds | |
MX2007010484A (es) | Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. | |
ATE542796T1 (de) | N-sulfonylcarboximidamidverbindungen als apoptosepromotoren | |
BRPI0615141A2 (pt) | inibidores pentacìclicos de quinase | |
MX2008001428A (es) | Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos. | |
TW200716561A (en) | P38 inhibitors and methods of use thereof | |
DE60329326D1 (de) | Tace inhibitoren | |
ATE533769T1 (de) | Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen |